Dry (Atrophic) Macular Degeneration-Pipeline Review, H1 2015

Dry (Atrophic) Macular Degeneration-Pipeline Review, H1 2015

  • Products Id :- GMDHC6595IDB
  • |
  • Pages: 128
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dry (Atrophic) Macular Degeneration-Pipeline Review, H1 2015


Global Markets Direct's, 'Dry (Atrophic) Macular Degeneration-Pipeline Review, H1 2015', provides an overview of the Dry (Atrophic) Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dry (Atrophic) Macular Degeneration and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Dry (Atrophic) Macular Degeneration Overview 9

Therapeutics Development 10

Pipeline Products for Dry (Atrophic) Macular Degeneration-Overview 10

Pipeline Products for Dry (Atrophic) Macular Degeneration-Comparative Analysis 11

Dry (Atrophic) Macular Degeneration-Therapeutics under Development by Companies 12

Dry (Atrophic) Macular Degeneration-Therapeutics under Investigation by Universities/Institutes 14

Dry (Atrophic) Macular Degeneration-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Dry (Atrophic) Macular Degeneration-Products under Development by Companies 19

Dry (Atrophic) Macular Degeneration-Products under Investigation by Universities/Institutes 21

Dry (Atrophic) Macular Degeneration-Companies Involved in Therapeutics Development 22

Acucela Inc. 22

Alexion Pharmaceuticals, Inc. 23

Alimera Sciences, Inc. 24

Apellis Pharmaceuticals, Inc. 25

Benitec Biopharma Limited 26

Bioheart, Inc. 27

Catalyst Biosciences, Inc. 28

Cell Cure Neurosciences, Ltd. 29

Eleven Biotherapeutics Inc. 30

Foamix Pharmaceuticals Ltd. 31

Genentech, Inc. 32

GenSight Biologics SA 33

GlaxoSmithKline plc 34

Icon Bioscience, Inc. 35

MacuCLEAR, Inc. 36

Neurotech Pharmaceuticals, Inc. 37

Ocata Therapeutics, Inc. 38

Ophthotech Corp. 39

pSivida Corp. 40

Sun Pharma Advanced Research Company Ltd. 41

Dry (Atrophic) Macular Degeneration-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

AdipoCell-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

APL-2-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

avacincaptad pegol sodium-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

EBI-028-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

eculizumab-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

emixustat hydrochloride-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

fluocinolone acetonide-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Gene Therapy for Ocular Diseases-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

GS-020-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

GSK-933776-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

HMR-59-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ICR-14967-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

lampalizumab-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

MA09-hRPE-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

MC-1101-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

methotrexate-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

minocycline Gel-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

NM-9405-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

NT-501-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

OpRegen-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

OpRegen Plus-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

RC-1 Alpha-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

RST-001-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Small Molecules for Age Related Macular Degeneration-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Small Molecules for AMD-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

TT-231-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Dry (Atrophic) Macular Degeneration-Recent Pipeline Updates 92

Dry (Atrophic) Macular Degeneration-Dormant Projects 120

Dry (Atrophic) Macular Degeneration-Discontinued Products 122

Dry (Atrophic) Macular Degeneration-Product Development Milestones 123

Featured News & Press Releases 123

Dec 17, 2013: Bioheart Announces Clinical Study for Dry Macular Degeneration 123

Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 123

Oct 01, 2013: Roche to present data on Lampalizumab at investor event 124

Aug 27, 2013: Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 124

Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference 126

Appendix 127

Methodology 127

Coverage 127

Secondary Research 127

Primary Research 127

Expert Panel Validation 127

Contact Us 127

Disclaimer 128

List of Tables

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2015 10

Number of Products under Development for Dry (Atrophic) Macular Degeneration-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Dry (Atrophic) Macular Degeneration-Pipeline by Acucela Inc., H1 2015 22

Dry (Atrophic) Macular Degeneration-Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 23

Dry (Atrophic) Macular Degeneration-Pipeline by Alimera Sciences, Inc., H1 2015 24

Dry (Atrophic) Macular Degeneration-Pipeline by Apellis Pharmaceuticals, Inc., H1 2015 25

Dry (Atrophic) Macular Degeneration-Pipeline by Benitec Biopharma Limited, H1 2015 26

Dry (Atrophic) Macular Degeneration-Pipeline by Bioheart, Inc., H1 2015 27

Dry (Atrophic) Macular Degeneration-Pipeline by Catalyst Biosciences, Inc., H1 2015 28

Dry (Atrophic) Macular Degeneration-Pipeline by Cell Cure Neurosciences, Ltd., H1 2015 29

Dry (Atrophic) Macular Degeneration-Pipeline by Eleven Biotherapeutics Inc., H1 2015 30

Dry (Atrophic) Macular Degeneration-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 31

Dry (Atrophic) Macular Degeneration-Pipeline by Genentech, Inc., H1 2015 32

Dry (Atrophic) Macular Degeneration-Pipeline by GenSight Biologics SA, H1 2015 33

Dry (Atrophic) Macular Degeneration-Pipeline by GlaxoSmithKline plc, H1 2015 34

Dry (Atrophic) Macular Degeneration-Pipeline by Icon Bioscience, Inc., H1 2015 35

Dry (Atrophic) Macular Degeneration-Pipeline by MacuCLEAR, Inc., H1 2015 36

Dry (Atrophic) Macular Degeneration-Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 37

Dry (Atrophic) Macular Degeneration-Pipeline by Ocata Therapeutics, Inc., H1 2015 38

Dry (Atrophic) Macular Degeneration-Pipeline by Ophthotech Corp., H1 2015 39

Dry (Atrophic) Macular Degeneration-Pipeline by pSivida Corp., H1 2015 40

Dry (Atrophic) Macular Degeneration-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 41

Assessment by Monotherapy Products, H1 2015 42

Number of Products by Stage and Target, H1 2015 44

Number of Products by Stage and Mechanism of Action, H1 2015 46

Number of Products by Stage and Route of Administration, H1 2015 48

Number of Products by Stage and Molecule Type, H1 2015 50

Dry (Atrophic) Macular Degeneration Therapeutics-Recent Pipeline Updates, H1 2015 92

Dry (Atrophic) Macular Degeneration-Dormant Projects, H1 2015 120

Dry (Atrophic) Macular Degeneration-Dormant Projects (Contd..1), H1 2015 121

Dry (Atrophic) Macular Degeneration-Discontinued Products, H1 2015 122

List of Figures

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2015 10

Number of Products under Development for Dry (Atrophic) Macular Degeneration-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 42

Number of Products by Top 10 Targets, H1 2015 43

Number of Products by Stage and Top 10 Targets, H1 2015 44

Number of Products by Top 10 Mechanism of Actions, H1 2015 45

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Top 10 Routes of Administration, H1 2015 47

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 48

Number of Products by Top 10 Molecule Types, H1 2015 49

Number of Products by Stage and Top 10 Molecule Types, H1 2015 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Acucela Inc.

Alexion Pharmaceuticals, Inc.

Alimera Sciences, Inc.

Apellis Pharmaceuticals, Inc.

Benitec Biopharma Limited

Bioheart, Inc.

Catalyst Biosciences, Inc.

Cell Cure Neurosciences, Ltd.

Eleven Biotherapeutics Inc.

Foamix Pharmaceuticals Ltd.

Genentech, Inc.

GenSight Biologics SA

GlaxoSmithKline plc

Icon Bioscience, Inc.

MacuCLEAR, Inc.

Neurotech Pharmaceuticals, Inc.

Ocata Therapeutics, Inc.

Ophthotech Corp.

pSivida Corp.

Sun Pharma Advanced Research Company Ltd.

Dry (Atrophic) Macular Degeneration Therapeutic Products under Development, Key Players in Dry (Atrophic) Macular Degeneration Therapeutics, Dry (Atrophic) Macular Degeneration Pipeline Overview, Dry (Atrophic) Macular Degeneration Pipeline, Dry (Atrophic) Macular Degeneration Pipeline Assessment

select a license

Single User License
USD 2000 INR 129780
Site License
USD 4000 INR 259560
Corporate User License
USD 6000 INR 389340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com